2seventy bio (TSVT) Stock Analysis

What 2seventy bio does

2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to TSVT

Broad-market and Healthcare sector ETFs an investor holding 2seventy bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TSVT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for 2seventy bio?

2seventy bio trades under the ticker TSVT on NASDAQ.

Which exchange is TSVT listed on?

TSVT is listed on NASDAQ.

What sector does 2seventy bio operate in?

2seventy bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TSVT in a portfolio?

PortView shows TSVT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.